达格列净联合福辛普利治疗高血压合并糖尿病的效果分析

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1069 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探析应用联合策略(达格列净+福辛普利)治疗高血压伴糖尿病患者,对其降压、降糖及控制心力衰竭发生风险的影响。方法选择某院2020年11月—2021年8月就诊的120例高血压合并糖尿病患者, 采用随机数字表法分为观察组和对照组,每组60例。对照组给予单一福辛普利治疗,观察组给予达格列净联合福辛普利治疗,连续治疗2个月。对比2组患者血压控制指标[24 h收缩压(SBP)、舒张压(DBP)]、血糖控制指标[空腹血糖(FBG)、糖化血红蛋白(HbA1c)]、心室重构相关参数[右心室的收缩末期容积(RVESV)、舒张末期容积(RVEDV)、左心室重构指数(LVRI)]、心力衰竭发生率。结果治疗前,2组各指标差异均无统计学意义(P ＞0.05);治疗后观察组FBG、HbA1c分别为(7.11±1.47)mmol/L、 (7.22±1.52)%,低于对照组的(7.93±2.05)mmol/L、(8.14±1.67)%(t=2.518、3.156,P＜0.05);治疗后观察组24 h SBP、24 h DBP分别为(126.35±5.41)mm Hg、(75.49±4.37)mm Hg,低于对照组的(130.03±5.56)mm Hg 、(84.29±5.18)mm Hg(t=3.674、10.058,P＜0.05)。观察组和对照组心力衰竭发生率分别为0.00%、3.33% 、不良反应率发生率分别为6.67%、5.00%(P均＞0.05)。结论联合策略(达格列净+福辛普利)治疗高血压伴糖尿病的临床效果显著,能够控制心力衰竭发生风险,有效地降糖、降压。　

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	战玲
	宋杰
	杨姗姗

关键词 ：达格列净, 福辛普利, 高血压, 糖尿病, 心力衰竭

Abstract：Objective To investigate the effects of the combination strategy (dapagliflozin + fosinopril) in the treatment of hypertensive patients with diabetes, on its antihypertensive, hypoglycemic, and control of the risk of heart failure. Methods A total of 120 patients with hypertension and diabetes mellitus who visited a hospital from November 2020 to August 2021 were selected and divided into 60 cases in the observation group and control group respectively by the random number table method. The control group was treated with single fosinopril, and the observation group was treated with dapagliflozin plus fosinopril for 2 months. The blood pressure control indexes , glycemic control indexes , ventricular remodeling related parameters , and heart failure incidence rates were compared between the two groups. Results Before treatment, there was no significant difference between the two groups (P>0.05). The FBG and HbA1c in the post-treatment observation group were (7.11±1.47) mmol/L and (7.22±1.52)%, respectively, which were lower than those in the control group: (7.93±2.05) mmol/L and (8.14±1.67)%, respectively (t=2.518, 3.156, P<0.05). After treatment, the 24 h SBP and 24 h DBP in the observation group were (126.35±5.41) mmHg and (75.49±4.37) mmHg, respectively, which were lower than those in the control group: (130.03±5.56) mmHg and (84.29±5.18) mmHg, respectively (t=3.674, 10.058, P<0.05). The incidence rates of heart failure in the observation group and the control group were 0.00% and 3.33%, respectively, and the incidence rates of adverse reactions in the observation group and the control group were 6.67% and 5.00%, respectively (both P>0.05). Conclusion The combined strategy (dapagliflozin + fosinopril) has a significant clinical effect in the treatment of hypertension with diabetes, which can control the risk of heart failure, and effectively lower blood sugar and blood pressure.

Key words： Dapagliflozin Fosinopril Hypertension Diabetes Heart failure

收稿日期: 2022-02-28

ZTFLH:

R453

作者简介: 战玲(1964—),女,黑龙江人,主任医师,本科学历,主要从事内科高血压、糖尿病、冠心病、脑卒中、慢阻肺、骨质疏松疾病的诊治。

引用本文:

战玲,宋杰,杨姗姗. 达格列净联合福辛普利治疗高血压合并糖尿病的效果分析[J]. 中国校医, 2022, 36(12): 948-951.
ZHAN Ling, SONG Jie, YANG Shan-shan. Effect of dapagliflozin combined with fosinopril on treatment of hypertension and diabetes. Chinese Journal of School Doctor, 2022, 36(12): 948-951.

链接本文:

https://www.zgxyzz.org.cn/CN/ 或 https://www.zgxyzz.org.cn/CN/Y2022/V36/I12/948

[1] 常康慨,朱伟,郭忠欣,等.老年糖尿病合并高血压患者的预防保健分析[J].中国社区医师,2021,37(2):172-173.
[2] Yamazaki D,Hitomi H,Nishiyama A. Hypertension with diabetesmellitus complications[J].Hypertens Res,2018,41(3):147-156.
[3] 张腾云,郭泉滢,田元生.复方羚角降压片联合福辛普利治疗原发性高血压的临床研究[J].现代药物与临床,2021,36(3):556-560.
[4] 张邻川,夏成功,唐文明,等.达格列净片治疗2型糖尿病合并慢性心力衰竭患者的临床研究[J].中国临床药理学杂志,2021,37(19):2573-2576,2595.
[5] Kosiborod MN,Jhund PS,Docherty KF,et al. Effects of dapagliflozinon symptoms,function,and quality of life in patients with heart failureand reduced ejection fraction:Results from the DAPA-HF Trial[J].Circulation,2020,141(2):90-99.
[6] 孙纬纬.不同性别2型糖尿病患者血尿酸与BMI血压血脂的相关性研究[J].中国校医,2019,33(1):10-11,14.
[7] 中华医学会糖尿病学分会,国家基层糖尿病防治管理办公室.国家基层糖尿病防治管理指南(2018)[J].中华内科杂志,2018,57(12):885-893.
[8] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[9] 齐建翠.阿托伐他汀钙联合硫酸氢氯吡格雷治疗糖尿病周围血管病疗效分析[J].中国校医,2021,35(6):453-454,457.
[10] Alencherry B,Laffin LJ. Treatment of Hypertension in Patientswith Diabetes Mellitus:a Contemporary Approach[J].Curr CardiolRep,2021,23(3):14.
[11] 王宁,蔺千.福辛普利联合氨氯地平对糖尿病合并高血压患者血清转化生长因子-β1、醛固酮和C反应蛋白的影响[J].岭南心血管病杂志,2021,27(1):62-66.
[12] Xue C,Zhou C,Yang B,et al. Comparison of efficacy and safetybetween benidipine and hydrochlorothiazide in fosinopril-treatedhypertensive patients with chronic kidney disease:Protocol for arandomised controlled trial[J]. BMJ Open,2017,7(2):e013672.
[13] 解丹丹,巫婷婷,赵晓彤,等.达格列净通过丝氨酸/苏氨酸蛋白激酶/内皮型一氧化氮合酶途径调节高糖环境下的内皮祖细胞功能[J].安徽医科大学学报,2022,57(6):957-962.
[14] 周星璐,陆建灿,孟盈,等.达格列净对2型糖尿病患者糖代谢、脂代谢状态及肾损伤标志物水平的影响[J].实用临床医药杂志,2021,25(5):74-78.
[15] 孙韫琪.福辛普利联合羟苯磺酸钙对糖尿病肾病血管内皮功能及氧化应激的改善效果[J].中国民康医学. 2020,32(23):42-45.